Why the study?
Does single-agent mitoxantrone improve response rates and survival in patients with advanced breast cancer?
Does single-agent mitoxantrone improve response rates and survival in patients with advanced breast cancer?
Single-agent mitoxantrone provides a 15% response rate at 6 months in advanced breast cancer, with stable disease correlating with a 9-month survival benefit over progressive disease.
Answers are grounded in this paper and cite their sources.
Modest activity seen with mitoxantrone in advanced breast cancer; leaves open its comparative role versus modern therapies in prospective trials.
We have treated 76 patients with advanced breast cancer with single-agent mitoxantrone: all had previously received hormone therapy and 30 patients had also received prior chemotherapy. The overall response rate at 6 months was 15%, with a further 22% having static disease. Responding and static patients had similar survival curves and were grouped together as patients with "stable disease." Patients with stable disease had a significantly longer survival than patients with progressive disease (p less than 0.001); the median difference in survival was 9 months.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: